BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 26193702)

  • 1. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
    Liu B; Chen S; Guan Y; Chen L
    PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.
    Aboulnasr F; Hazari S; Nayak S; Chandra PK; Panigrahi R; Ferraris P; Chava S; Kurt R; Song K; Dash A; Balart LA; Garry RF; Wu T; Dash S
    PLoS One; 2015; 10(12):e0141655. PubMed ID: 26657215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MxA is a positive regulator of type I IFN signaling in HCV infection.
    Shi X; Jiao B; Chen Y; Li S; Chen L
    J Med Virol; 2017 Dec; 89(12):2173-2180. PubMed ID: 28561372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis.
    Chen Y; Jiao B; Yao M; Shi X; Zheng Z; Li S; Chen L
    Virus Res; 2017 Jan; 227():231-239. PubMed ID: 27777077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
    Marcello T; Grakoui A; Barba-Spaeth G; Machlin ES; Kotenko SV; MacDonald MR; Rice CM
    Gastroenterology; 2006 Dec; 131(6):1887-98. PubMed ID: 17087946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha.
    Zhao LJ; He SF; Liu Y; Zhao P; Bian ZQ; Qi ZT
    Cell Physiol Biochem; 2016; 40(1-2):77-90. PubMed ID: 27855377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway.
    Zhang L; Jilg N; Shao RX; Lin W; Fusco DN; Zhao H; Goto K; Peng LF; Chen WC; Chung RT
    J Hepatol; 2011 Aug; 55(2):289-98. PubMed ID: 21147189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
    Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
    Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients.
    Lee CM; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH; Yen YH
    J Formos Med Assoc; 2016 Jun; 115(6):440-4. PubMed ID: 26786212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
    Huang Y; Feld JJ; Sapp RK; Nanda S; Lin JH; Blatt LM; Fried MW; Murthy K; Liang TJ
    Gastroenterology; 2007 Feb; 132(2):733-44. PubMed ID: 17258724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells.
    Hirano K; Ichikawa T; Nakao K; Matsumoto A; Miyaaki H; Shibata H; Eguchi S; Takatsuki M; Ikeda M; Yamasaki H; Kato N; Kanematsu T; Ishii N; Eguchi K
    Liver Transpl; 2008 Mar; 14(3):292-8. PubMed ID: 18306331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
    Zhu H; Butera M; Nelson DR; Liu C
    Virol J; 2005 Sep; 2():80. PubMed ID: 16146571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT1 is essential for the inhibition of hepatitis C virus replication by interferon-λ but not by interferon-α.
    Yamauchi S; Takeuchi K; Chihara K; Honjoh C; Kato Y; Yoshiki H; Hotta H; Sada K
    Sci Rep; 2016 Dec; 6():38336. PubMed ID: 27929099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin inhibits respiratory syncytial virus replication by regulating the MiR-155/SOCS1/STAT1 signaling pathway.
    Wang S; Ling Y; Yao Y; Zheng G; Chen W
    Virol J; 2020 Nov; 17(1):187. PubMed ID: 33239033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture.
    Kurt R; Chandra PK; Aboulnasr F; Panigrahi R; Ferraris P; Aydin Y; Reiss K; Wu T; Balart LA; Dash S
    PLoS One; 2015; 10(5):e0125962. PubMed ID: 25961570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.
    Mukherjee A; Di Bisceglie AM; Ray RB
    J Virol; 2015 Mar; 89(6):3356-65. PubMed ID: 25589644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.
    Lin W; Zhu C; Hong J; Zhao L; Jilg N; Fusco DN; Schaefer EA; Brisac C; Liu X; Peng LF; Xu Q; Chung RT
    J Hepatol; 2015 May; 62(5):1024-32. PubMed ID: 25481564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells.
    Wonganan O; He YJ; Shen XF; Wongkrajang K; Suksamrarn A; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2017 Dec; 336():31-39. PubMed ID: 29031523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.